Abstract:In recent study, in order to improve the bioavailability of endomorphin-1 (EM-1), we designed and synthesized a series of novel EM-1 analogs by replacement of L-Pro2 by β-Pro, D-Ala or Sar, together with C-terminal oligoarginine-conjugation. Our results indicated that the introduction of D-Ala and β-Pro in position 2, along with oligoarginine-conjugation, didn't significantly decrease the μ-affinity and in vitro bioactivity, and the enhancement of arginine residues did not markedly influence the μ-affinity of these analogs. All analogs displayed a significant enhancement of stability, which may be due to increased resistance to proline-specific enzymatic degradation. Moreover, following intracerebroventricular (i.c.v.) administration, analogs 1, 2, 4 and 5 produced significant antinociception and increased duration of action, with the ED50 values being about 1.8- to 4.2-fold less potent than that of EM-1. In addition, our results indicated that no significant antinociceptive activity of EM-1 was seen following subcutaneous (s.c.) injection, whereas analogs 1, 2, 4 and 5 with equimolar dose induced significant and prolonged antinociception by an opioid and central mechanism. Herein, we further examined the gastrointestinal transit and colonic propulsive latencies of EM-1 and its four analogs administered centrally and peripherally. I.c.v. administration of EM-1 and analogs 1, 2, 4 and 5 significantly delayed gastrointestinal transit and colonic bead propulsion in mice, but the inhibitory effects induced by these analogs were largely attenuated. It is noteworthy that no significant gastrointestinal side effects induced by these four analogs were observed after s.c. administration. Our results demonstrated that combined modifications of EM-1 with unnatural amino acid substitutions and oligoarginine-conjugation gave an efficient strategy to improve the analgesic profile of EM-1 analogs but with less gastrointestinal side effects when administered peripherally.

Endomorphin-1 analogs with enhanced metabolic stability and systemic analgesic activity: design, synthesis, and pharmacological characterization.

Endomorphin-1 Analogs Containing Α-Methyl-β-amino Acids Exhibit Potent Analgesic Activity after Peripheral Administration.

Design, Synthesis, and Biological Activity of New Endomorphin Analogs with Multi-Site Modifications

Design, Synthesis, and Evaluation of New Endomorphin Analogs with Enhanced Central Antinociception after Peripheral Administration.

Novel endomorphin-1 analogs with C-terminal oligoarginine-conjugation display systemic antinociceptive activity with less gastrointestinal side effects.

MEL-N16: A Series of Novel Endomorphin Analogs with Good Analgesic Activity and a Favorable Side Effect Profile

Structure-Constrained Endomorphin Analogs Display Differential Antinociceptive Mechanisms in Mice after Spinal Administration

Novel Cyclic Endomorphin Analogues with Multiple Modifications and Oligoarginine Vector Exhibit Potent Antinociception with Reduced Opioid-like Side Effects

Endomorphin-1 Analogs with Oligoarginine-Conjugation at C-terminus Produce Potent Antinociception with Reduced Opioid Tolerance in Paw Withdrawal Test.

Design, Synthesis, and Pharmacological Characterization of Novel Endomorphin-1 Analogues As Extremely Potent Μ-Opioid Agonists.

Endomorphin-2 Analogs with C-terminal Esterification Produce Potent Systemic Antinociception with Reduced Tolerance and Gastrointestinal Side Effects

Structure–activity Relationship of the Novel Bivalent and C-terminal Modified Analogues of Endomorphin-2

Endomorphins: Promising Endogenous Opioid Peptides for the Development of Novel Analgesics

Cyclic Glycopeptide Analogs of Endomorphin-1 Provide Highly Effective Antinociception in Male and Female Mice

Novel Endomorphin Analogues CEMR-1 and CEMR-2 Produce Potent and Long-Lasting Antinociception with a Favourable Side Effect Profile at the Spinal Level

Synthesis and Biological Evaluations of Novel Endomorphin Analogues Containing Α-Hydroxy-β-phenylalanine (AHPBA) Displaying Mixed Μ/δ Opioid Receptor Agonist and Δ Opioid Receptor Antagonist Activities.

Endomorphins: Potential Roles and Therapeutic Indications in the Development of Opioid Peptide Analgesic Drugs

Endomorphin-1 Analogues (mels) Penetrate the Blood–brain Barrier and Exhibit Good Analgesic Effects with Minimal Side Effects

Endomorphin-2 Analogs with C-terminal Esterification Display Potent Antinociceptive Effects in the Formalin Pain Test in Mice.

Utilization of Combined Chemical Modifications to Enhance the Blood-Brain Barrier Permeability and Pharmacological Activity of Endomorphin-1

Design, Synthesis, and Biological Evaluation of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan Derivatives As Peripheral Selective Μ Opioid Receptor Agents.